Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients

Shin, Sei One; Jang, Bo‐Hyoung; Park, Kyoung Sun; Lee, Jin Wook; Chae, Min Soo; Kim, Nam Hoon; Suh, Hae Sun; Han, Sangheon; Min, Sun Young; Baek, Sun Kyung; Lim, Young‐Jun; Hwang, Deok‐Sang

doi:10.1097/md.0000000000017260

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moxibustion has been shown to have a good effect on treating tumour-related symptoms, such as fatigue, 3,4 pain, [5][6][7] anorexia 8 and depression, 9 and on alleviating surgery-and chemotherapy-induced adverse effects. 10 However, its antitumour effect on NSCLC remains largely unexplored.…”

Section: Introductionmentioning

confidence: 99%

Grain‐sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non–small cell lung cancer

Shen

Gong

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer‐related death worldwide, and non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer diagnoses. As an ancient therapy, moxibustion has been used to treat cancer‐related symptoms in clinical practice. However, its antitumour effect on NSCLC remains largely unexplored. In the present study, a Lewis lung cancer (LLC) xenograft tumour model was established, and grain‐sized moxibustion (gMoxi) was performed at the acupoint of Zusanli (ST36). Flow cytometry and RNA sequencing (RNA‐Seq) were used to access the immune cell phenotype, cytotoxicity and gene expression. PK136, propranolol and epinephrine were used for natural killer (NK) cell depletion, β‐adrenoceptor blockade and activation, respectively. Results showed that gMoxi significantly inhibited LLC tumour growth. Moreover, gMoxi significantly increased the proportion, infiltration and activation of NK cells, whereas it did not affect CD4+ and CD8+ T cells. NK cell depletion reversed gMoxi‐mediated tumour regression. LLC tumour RNA‐Seq indicated that these effects might be related to the inhibition of adrenergic signalling. Surely, β‐blocker propranolol clearly inhibited LLC tumour growth and promoted NK cells, and gMoxi no longer increased tumour regression and promoted NK cells after propranolol treatment. Epinephrine could inhibit NK cell activity, and gMoxi significantly inhibited tumour growth and promoted NK cells after epinephrine treatment. These results demonstrated that gMoxi could promote NK cell antitumour immunity by inhibiting adrenergic signalling, suggesting that gMoxi could be used as a promising therapeutic regimen for the treatment of NSCLC, and it had a great potential in NK cell–based cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Grain‐sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non–small cell lung cancer

Shen

Gong

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

Clinical evidence of acupuncture and related therapy in patients with cancer-pain

et al. 2020

View full text Add to dashboard Cite

Background: Cancer pain (CP) is one of the common complications of cancer. During the treatment, oral medication, radiotherapy and chemotherapy bring certain adverse reactions to patients with CP; a safe way to treat this disease is necessary. Acupuncture and related therapies for CP with few side effects have been gradually accepted. But at present the evidence is insufficient, the related research is not thorough enough. The purpose of this study was to investigate the efficacy and safety of acupuncture and related therapies for CP. Methods: The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines were used to design this protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analysis. An electronic search will be conducted in Medline, Embase, and the Cochrane Central Register of Controlled Trials databases through January 2020. The search will be conducted in English. Risk of bias will be assessed by the Cochrane Collaboration tool and the collected evidence will be nar-ratively synthesized. We will also perform a meta-analysis to pool estimates from studies considered to be homogenous. Subgroup analyses will be based on intervention or overall bias. The strength of evidence will be evaluated by the Grading of Recommendations, Assessment, Development and Evaluation scale. Results: This systematic review will summarize high quality clinical evidence to assess and appraise the effectiveness and safety of acupuncture and related therapies for CP patients. Conclusion: The meta-analysis will assess evidence from randomized controlled trials of acupuncture and related therapies and CP types. INPLASY registration number: INPLASY202040129.

show abstract

Research and Practice of Moxa Sticks Based on Big Data to Improve Insomnia Acupoint Selection for Cancer Patients

赵¹

2022

View full text Add to dashboard Cite

Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients

Cited by 3 publications

References 17 publications

Grain‐sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non–small cell lung cancer

Grain‐sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non–small cell lung cancer

Clinical evidence of acupuncture and related therapy in patients with cancer-pain

Research and Practice of Moxa Sticks Based on Big Data to Improve Insomnia Acupoint Selection for Cancer Patients

Contact Info

Product

Resources

About